The Role of Irisin in Cancer Disease

• Main Authors: Agnieszka Pinkowska, Marzenna Podhorska-Okołów, Piotr Dzięgiel, Katarzyna Nowińska
• Format: Article
• Language: English
• Published: MDPI AG 2021-06-01
• Series: Cells
• Subjects: Irisin; FNDC5; cancer; proliferation; migration; epithelial–mesenchymal transition
• Online Access: https://www.mdpi.com/2073-4409/10/6/1479

Irisin (Ir) is an adipomyokine that is involved in the regulation of metabolic processes. It also influences processes related to inflammation, including cancer. Initially, Ir was considered a hormone secreted by skeletal muscles in response to physical exercise. Further studies showed that Ir is also present in other healthy tissues, organs, and plasma. It influences the change in phenotype of white adipose tissue (WAT) into brown adipose tissue (BAT). It increases mitochondrial biogenesis and affects the expression of thermogenin (UCP1). This adipomyokine has also been found in many tumor tissues and in the serum of cancer patients. Studies are underway to determine the association between Ir and carcinogenesis. It has been confirmed that Ir inhibits in vitro proliferation, migration, and invasion. It is involved in the inhibition of epithelial–mesenchymal transition (EMT). Additionally, Ir affects the expression of the transcription factor Snail, which is involved in EMT, and inhibits transcription of the gene encoding E-cadherin, which is characteristic of epithelial-derived cells. Many studies have been performed to determine the role of Ir in physiological and pathological processes. Further detailed studies should determine more precisely the effect of Ir on the body in health and disease.